Trial · NCT07883564
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Binary indicator of LDL-C <55 mg/dL for patients with a recent MI or coronary stent and <70 mg/dL for patients undergoing PCI with no MI and/or ischemic heart disease or with a CAC score of at least 300 at 6-month post visit, with time to event. | Within 6-months post qualifying event. | LDL-C level/goal attainment per guidelines. LDL-C laboratory testing. |
| Primary | Binary indicator of patients who received LDL-C testing, with time to event. | Up to 365 days following qualifying event. | LDL-C laboratory testing. |
| Primary | Binary indicator of patients in whom lipid lowering therapy was initiated/intensified within the first six months after index event. | Within 6-months post qualifying event. | Any change in prescriptions/dosages of lipid lowering medications (statins, ezetimibe, BAS, PCSK9 inhibitors, bempedoic acid +/- ezetimibe, fibrates, prescription OM3FA). |
| Secondary | Persistence of cardiovascular risk goals after being discharged from the APP pathway strategy: Prescription of GLP1/SGLT2 inhibitors | Up to 365 days following qualifying event. | Prescription or removal of GLP1/SGLT2 inhibitor medications. |
| Secondary | Persistence of cardiovascular risk after discharge from the APP pathway strategy: Cardiac Rehab | Up to 365 days following qualifying event. | Binary indication of whether cardiac rehab was ordered and initiated. |
| Secondary | Persistence of cardiovascular risk after discharge from the APP pathway strategy: Blood Pressure | Up to 365 days following qualifying event. | Self-reported home measurement or in-office measurement of blood pressure. |
| Secondary | Persistence of cardiovascular risk after discharge from the APP pathway strategy: BMI | Up to 365 days following qualifying event. | Height in inches and weight in pounds as measured during office visit will be combined to report BMI in lbs/in\^2. |
| Secondary | Persistence of cardiovascular risk after discharge from the APP pathway strategy: Smoking Status | Up to 365 days following qualifying event. | Binary indicator of smoking status. |
| Secondary | Binary indicator of LDL-C <55 mg/dL for patients with a recent MI or coronary stent and <70 mg/dL patients undergoing PCI with no MI and/or ischemic heart disease and for those with a CAC score > 300 at 3- and 12-month post visit, with time to event. | Up to 365 days following qualifying event. | LDL-C laboratory testing, LDL-C level/goal attainment per guidelines. |
| Secondary | Binary indicator of patients in whom LLT was initiated/intensified at the 3- and 12-month visits post-index. | Up to 365 days following qualifying event. | Any change in prescriptions/dosages of lipid lowering medications (statins, ezetimibe, BAS, PCSK9 inhibitors, bempedoic acid +/- ezetimibe, fibrates, prescription OM3FA). |
| Secondary | Binary indicator of patients with noted transition to non-smoking status, with time to event. | Up to 365 days following qualifying event. | Subset of smokers at index event. |
| Secondary | Binary indicator of any prescribed GLP1 agonist or SGLT2 inhibitor within 3, 6, and 12-month follow-up periods post qualifying event. | Up to 365 days following qualifying event. | Subset of diagnosed diabetics and pre-diabetics at index. Any changes in prescriptions/dosages of GLP1, SGLT2i medications. |
| Secondary | Percentage of patients who achieved their blood pressure goal. | Up to 365 days following qualifying event. | Time to event analyses. |
| Secondary | Implementation outcome: Acceptability | From the implementation initiation through study completion, approximately 20 months. | Patient and clinician ratings of acceptability of strategies measured via survey. |
| Secondary | Implementation Outcome: Reach | From the implementation initiation through study completion, approximately 20 months. | Proportion of patients who received an implementation strategy, which strategy(ies), and their characteristics. |
| Secondary | Implementation Outcome: Adoption | From the implementation initiation through study completion, approximately 20 months. | Proportion of clinicians who used a strategy and their characteristics. |
| Secondary | Implementation Outcome: Fidelity | From the implementation initiation through study completion, approximately 20 months. | Adaptations to how strategies are implemented across healthcare sites (descriptive via logs). |
| Secondary | Implementation Outcome: Cost | From the implementation initiation through study completion, approximately 20 months. | The cost of each strategy deployed at each site via a profit/loss statement. |
| Other | Adverse clinical outcomes across follow-up (e.g., type of event, date of event) | Up to 365 days following qualifying event. | Stroke, MI, PCI, CABG, hospitalization for UA, death (CV or any death) |
| Other | Adverse reactions to LLT (e.g., type of reaction, date of reaction) | Up to 365 days following qualifying event. | EHR data on adverse reactions to LLTs. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07883564/registered